样式: 排序: IF: - GO 导出 标记为已读
-
US Government, states reign in insurers' prior authorisation Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-20 Bryant Furlow
-
Local ablation in pancreatic cancer: some answers and more questions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Zachary T Berman, Rebekah R White
-
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Florentine E F Timmer MD, Bart Geboers MD, Alette H Ruarus MD, Laurien G P H Vroomen MD, Evelien A C Schouten MSc, Susan van der Lei MD, Danielle J W Vos MD, Madelon Dijkstra MD, Hannah H Schulz MD, Joyce Bakker BSc, Bente A T van den Bemd MD, Petrousjka M van den Tol MD, Robbert S Puijk MD, Birgit I Lissenberg-Witte PhD, Prof Tanja D de Gruijl PhD, Jan J J de Vries MD, Frank J Lagerwaard MD, Hester
Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible
-
Should a no-drain policy after distal pancreatectomy become standard? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-16 Ulla Klaiber, Oliver Strobel
-
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-16 Eduard A van Bodegraven MD, Alberto Balduzzi MD, Tess M E van Ramshorst MD, Prof Giuseppe Malleo MD, Frederique L Vissers MD, Jony van Hilst MD, Sebastiaan Festen MD, Prof Mohammad Abu Hilal MD, Prof Horacio J Asbun MD, Nynke Michiels MD, Prof Bas Groot Koerkamp MD, Prof Olivier R C Busch MD, Freek Daams MD, Prof Misha D P Luyer MD, Marco Ramera MD, Giovanni Marchegiani MD, Prof Joost M Klaase MD,
Prophylactic passive abdominal drainage is standard practice after distal pancreatectomy. This approach aims to mitigate the consequences of postoperative pancreatic fistula (POPF) but its added value, especially in patients at low risk of POPF, is currently being debated. We aimed to assess the non-inferiority of a no-drain policy in patients after distal pancreatectomy. In this international, multicentre
-
Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-13 Raghav Sundar, Elizabeth C Smyth
-
-
You Are What You Eat: a Twin Experiment Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, i, e, , S, h, e, r, w, o, o, d, -, M, a, r, t, i, n
-
Research in Brief Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, y, , B, a, k, e, r
-
Resmetirom for NASH: balancing promise and prudence Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , G, a, s, t, r, o, e, n, t, e, r, o, l, o, g, y, , &, , H, e, p, a, t, o, l, o, g, y
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Marlijne C G de Graaf, Daniel Keszthelyi, Fred J P H Brouns, Louise Dye, Daisy M A E Jonkers, on behalf of all authors
-
The DESTIN trial: to step up or not? – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Ji Young Bang, Shyam Varadarajulu
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Oscar Cahyadi, Vinay Dhir, John Leeds, Enrique de-Madaria, Nadeem Tehami
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Xiang-Lei Yuan, Bing Hu
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Daisuke Murakami, Masayuki Yamato, Takayoshi Nishino, Makoto Arai
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Avinash Tiwari, Mayank Mehrotra, Ajmal Hasan, Jaya Agarwal, Gaurav Kumar Singh
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
-
Robotic pancreatoduodenectomy: preparing for the future Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-28 Elisa Bannone, Giovanni Marchegiani
-
Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-28 Prof Qu Liu MD, Mengyang Li MD, Prof Yuanxing Gao MD, Prof Tao Jiang MD, Prof Bing Han MD, Prof Guodong Zhao MD, Chao Lin MD, Prof Wan Yee Lau MD, Prof Zhiming Zhao MD, Prof Rong Liu MD
The flexibility of the robotic system in resection and reconstruction provides potential benefits in pancreaticoduodenectomy. Increasingly, robotic pancreaticoduodenectomy (RPD) has been reported with favourable outcomes, but high-level evidence is still scarce. We aimed to compare the short-term postoperative outcomes of RPD with those of open pancreaticoduodenectomy (OPD), and hypothesised that postoperative
-
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-22 Nurulamin M Noor PhD, James C Lee PhD, Simon Bond PhD, Francis Dowling BSc, Biljana Brezina MSc, Kamal V Patel MRCP, Tariq Ahmad DPhil, Paul J Banim MD, James W Berrill MD, Rachel Cooney DPhil, Juan De La Revilla Negro MD, Shanika de Silva MRCP, Shahida Din PhD, Dharmaraj Durai PhD, John N Gordon DM, Prof Peter M Irving MD, Matthew Johnson MD, Alexandra J Kent DPhil, Klaartje B Kok PhD, Prof Gordon
Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies. PROFILE (PRedicting
-
Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-22 Thomas P Chapman, Tariq Ahmad, Jack Satsangi
-
Can genetically engineered pig livers offer patients precious time? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-16 B, r, y, a, n, t, , F, u, r, l, o, w
-
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Nicolas Minier PhD, Alice Nanelin Guingané PhD, Prof Edith Okeke MD, Edford Sinkala MD, Asgeir Johannessen PhD, Monique I Andersson MD, Pantong Davwar MD, Prof Hailemichael Desalegn PhD, Mary Duguru MD, Prof Fatou Fall MD, Prof Souleyman Mboup PhD, Tongai Maponga PhD, Prof Philippa C Matthews PhD, Adrià Ramírez Mena MD, Gibril Ndow PhD, Stian M S Orlien PhD, Nicholas Riches MBChB, Prof Moussa Seydi
Hepatitis B virus (HBV) elimination requires expanding and decentralising HBV care services. However, peripheral health facilities lack access to diagnostic tools to assess eligibility for antiviral therapy. Through the Hepatitis B in Africa Collaborative Network (HEPSANET), we aimed to develop and evaluate a score using tests generally available at lower-level facilities, to simplify the evaluation
-
A new tool for assessing hepatitis B treatment eligibility in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Serge Ouoba, Moussa Lingani
-
WHO hepatitis C elimination targets: the global equity challenge Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Katherine Heath, Andrew Hill
-
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Prof Alison D Marshall PhD, Alex R Willing BAdvSci, Abe Kairouz BPysch, Evan B Cunningham PhD, Alice Wheeler BPysch, Nicholas O’Brien MPH, Vidura Perera MPH, John W Ward MD, Lindsey Hiebert MPH, Prof Louisa Degenhardt PhD, Behzad Hajarizadeh PhD, Samantha Colledge PhD, Prof Matthew Hickman PhD, Danielle Jawad MPH, Prof Jeffrey V Lazarus PhD, Prof Gail V Matthews PhD, Andrew Scheibe MD, Prof Peter Vickerman
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV treatment, permitting non-specialists to manage patients without advanced liver disease. We collected and reviewed global data on the registration and reimbursement (government subsidised) of HCV therapies, including restrictions on reimbursement. Primary
-
Eliminating viral hepatitis: no room for complacency Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 R, o, b, , B, r, i, e, r, l, e, y
-
Harnessing the power of civil society to achieve hepatitis elimination Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Danjuma Adda, Jessica Hicks, Cary James, Alexandra Smith
-
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Prof Graham S Cooke DPhil, Barnaby Flower PhD, Evan Cunningham PhD, Alison D Marshall PhD, Prof Jeffrey V Lazarus PhD, Adam Palayew PhD, Prof Jidong Jia MD PhD, Prof Rakesh Aggarwal MD DM, Prof Mamum Al-Mahtab PhD, Prof Yashuito Tanaka PhD, Prof Sook-Hyang Jeong PhD, Kittiyod Poovorawan MD, Prof Imam Waked PhD, Lindsey Hiebert MPH, Pham M Khue PhD, Prof Jason Grebely PhD, Prof Diana Alcantara-Payawal
The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries
-
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Hanna Amanuel Tesfahunei, Mohammed Abdulaziz, Nafiisah Chotun, John W Ward, Mohamed Hassany, Jean Kaseya
-
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Marion Delphin PhD, Khadija Said Mohammed MSc, Louise O Downs MBBS, Sheila F Lumley BMBCh, Elizabeth Waddilove MSc, Dorcas Okanda MSc, Nadia Aliyan MD, Marije Van Schalkwyk MD, Motswedi Anderson PhD, Ponsiano Ocama PhD, Tongai Maponga PhD, Judith Torimiro PhD, Prof Collins Iwuji MD, Prof Thumbi Ndung'u PhD, Prof Philippa C Matthews DPhil, Jantjie Taljaard MMed
The WHO African region bears a disproportionate burden of morbidity and mortality related to chronic hepatitis B virus (HBV) infection and accounts for an estimated 70% of new HBV infections worldwide. We investigated the extent to which HBV clinical trials represented populations in this region by searching the WHO International Clinical Trials Registry Platform and for interventional clinical trials
-
The COSMIC-312 study: will it shape future combination therapies for advanced hepatocellular carcinoma? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-13 Anna Saborowski, Ana Lleo
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-13 Thomas Yau MD, Prof Ahmed Kaseb MD, Prof Ann-Lii Cheng MD, Prof Shukui Qin MD, Prof Andrew X Zhu MD, Prof Stephen L Chan MD, Tamar Melkadze MD, Wattana Sukeepaisarnjaroen MD, Valery Breder MD, Gontran Verset MD, Prof Edward Gane MD, Prof Ivan Borbath MD, Jose David Gomez Rangel MD, Prof Baek-Yeol Ryoo MD, Tamta Makharadze MD, Prof Philippe Merle MD, Fawzi Benzaghou MD, Steven Milwee PharmD, Zhong Wang
The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following
-
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Prof James O Lindsay PhD, Prof Daniel Hind PhD, Lizzie Swaby MSc, Hannah Berntsson MSc, Mike Bradburn MSc, Uday Bannur C FRCR, Jennifer Byrne PhD, Christopher Clarke FRCR, Lauren Desoysa MSc, Ben Dickins PhD, Shahida Din MBChB, Prof Richard Emsley PhD, Gemma A Foulds PhD, Prof John Gribben MD DSc, Prof Christopher Hawkey DM, Prof Peter M Irving MD, Majid Kazmi MBChB, Ellen Lee MSc, Amanda Loban PhD
A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population. This open-label, multicentre, randomised controlled
-
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2023 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07
-
Rusfertide for iron overload in haemochromatosis – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Kris V Kowdley, Nishit B Modi, Frank H Valone
-
An International Classification of Diseases code for gastric intestinal metaplasia: an opportunity for gastric cancer prevention Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Robert J Huang, M Constanza Camargo
-
-
Correction to Lancet Gastroenterol Hepatol 2024; 9: 110–23 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07
-
C'est difficile: an encounter with infection while taking antibiotics Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Mandip Aujla
-
Acute severe ulcerative colitis management: unanswered questions and latest insights Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Pauline Rivière, Christopher Li Wai Suen, María Chaparro, Peter De Cruz, Antonino Spinelli, David Laharie
-
Correction to Lancet Gastroenterol Hepatol 2024; 9: 83–91 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07
-
-
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 T, h, e, , E, d, i, t, o, r, s, , o, f, , T, h, e, , L, a, n, c, e, t, , G, a, s, t, r, o, e, n, t, e, r, o, l, o, g, y, , &, , H, e, p, a, t, o, l, o, g, y
-
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Rachele Ciccocioppo, Ludovit Gaspar
-
Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera, Mariane Christina Savio, Maria Paz Gimenez Villamil, Remo Panaccione, Siew C Ng, Gilaad G Kaplan, Paulo Gustavo Kotze
-
Rusfertide for iron overload in haemochromatosis Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Muhammad Uwais Ashraf, Debadrita Ray, Arka De, Reena Das, Ajay Duseja
-
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-05 Mohsan Subhani, Ashwin Dhanda, Adina Olaru, Louise Dunford, Nahid Ahmad, Andrew Wragg, Kate Frost, Justin Greenwood, Melinda King, Katy A Jones, William Rosenberg, Julia Sinclair, Stefan Rennick-Egglestone, Joanne R Morling, Krishna Patel, Stephen D Ryder
Abstract not available
-
Liver transplantation for acute-on-chronic liver failure Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-01 Florent Artru, Francesca Trovato, Maura Morrison, William Bernal, Mark McPhail
Acute-on-chronic liver failure (ACLF) occurs in the context of advanced liver disease and is associated with hepatic and extrahepatic organ failure, eventually leading to a major risk of short-term mortality. To date, there are very few effective therapeutic options for ACLF. In many cases, liver transplantation is the only life-saving treatment that has acceptable outcomes in carefully selected recipients
-
Covered versus bare-metal stenting of the mesenteric arteries in patients with chronic mesenteric ischaemia (CoBaGI): a multicentre, patient-blinded and investigator-blinded, randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-29 Luke G Terlouw MD, Louisa J D van Dijk PhD, Desirée van Noord PhD, Olaf J Bakker PhD, Diederik C Bijdevaate PhD, Nicole S Erler PhD, Bram Fioole PhD, Jihan Harki PhD, Daniel A F van den Heuvel MD, Jan Willem Hinnen PhD, Prof Jeroen J Kolkman PhD, Suzan Nikkessen MD, André S van Petersen PhD, Henk F M Smits PhD, Prof Hence J M Verhagen PhD, Annemarie C de Vries PhD, Prof Jean-Paul P M de Vries PhD,
Mesenteric artery stenting with a bare-metal stent is the current treatment for atherosclerotic chronic mesenteric ischaemia. Long-term patency of bare-metal stents is unsatisfactory due to in-stent intimal hyperplasia. Use of covered stents might improve long-term patency. We aimed to compare the patency of covered stents and bare-metal stents in patients with chronic mesenteric ischaemia. We conducted
-
Robust data on stenting for patients with chronic mesenteric ischaemia Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-29 Bernardo C Mendes, Randall R DeMartino
Abstract not available
-
Urgent need for lived experience in hepatitis B guideline development Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-22 Catherine Freeland, Wendy Lo, Kenneth Kabagambe, Su Wang, Danjuma Adda, Camilla S Graham, Robert Gish, Chari Cohen
Abstract not available
-
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-15 Knut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson, Jon-Helge Angelsen, Christina Biörserud, Bergthor Björnsson, Erling Audun Bringeland, Nils Elander, Herish Garresori, Jon Erik Grønbech, Johan Haux, Oskar Hemmingsson, Maria Gustafsson Liljefors, Tor Åge Myklebust, Linn Såve Nymo, Katriina Peltola, Per Pfeiffer, Ville Sallinen, Per Sandström, Ernesto Sparrelid, Sheraz Yaqub
Background In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
-
The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-15 David Henault, C Benedikt Westphalen, Grainne M O'Kane
Abstract not available
-
Transforming global hepatology training: a call for action Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-15 James Liu Yin, Sanjaya K Satapathy, James O'Beirne, Ponsiano Ocama, Osman Dar, Ajay Duseja, Thomas Schiano, Aftab Ala
Abstract not available
-
Promoting equity in inflammatory bowel disease: a global approach to care Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-11 Shaji Sebastian, Britta Siegmund, Fasika Teferra, Dermot P B McGovern, Natalia Sousa Freitas Queiroz, C Janneke van der Woude, Vishal Sharma
Abstract not available
-
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-09 Teus J Weijs, Hanneke W M van Laarhoven, Bas P L Wijnhoven, Jelle P Ruurda, Richard van Hillegersberg
Abstract not available
-
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-11 Mads Israelsen, Nikolaj Torp, Stine Johansen, Camilla Dalby Hansen, Emil Deleuran Hansen, Katrine Thorhauge, Johanne Kragh Hansen, Ida Villesen, Katrine Bech, Charlotte Wernberg, Peter Andersen, Katrine Prier Lindvig, Emmanuel A Tsochatzis, Maja Thiele, Mary E Rinella, Aleksander Krag
Background Steatotic liver disease is a new overarching term that includes metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related steatotic liver disease (MetALD), and alcohol-related liver disease (ALD). We aimed to validate the prognostic importance of MASLD, MetALD, and ALD as steatotic liver disease subclasses. Methods Between April 18, 2013
-
The role of past and present alcohol use in steatotic liver disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-11 Fredrik Åberg
Abstract not available
-
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-01-09 James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Much of the recognised health-care burden occurs in the minority of people with NAFLD who progress towards cirrhosis and require specialist follow-up, including risk stratification and hepatocellular carcinoma surveillance. NAFLD is projected to become the leading global cause of cirrhosis and hepatocellular